
SI-BONE Inc (SIBN) Stock Forecast & Price Target
SI-BONE Inc (SIBN) Analyst Ratings
Bulls say
SI-BONE is poised for increased revenue growth with the launch of their new INTRA Ti implant and the potential for new products targeting clinical adjacencies. The company also expects to generate positive EBITDA in 2026 and increase international market penetration, further driving revenue and profitability. Additionally, the recent strategic distribution partnership with Smith Nephew for trauma and spine products shows potential for deeper penetration into larger Tier 1 and 2 accounts, creating room for growth and solidifying SI-BONE's position as a leader in the minimally invasive sacroiliac joint fusion market.
Bears say
SI-BONE is facing competition in the market, their iFuse patents are set to expire, and their sales force and profitability may not execute as expected. Additionally, they are facing potential market dynamics and slower progress ramping profitability. Their upcoming product launches may serve as catalysts, but there are still risks to consider, such as competitive launches and potential challenges with ramping revenue and profitability. With a slower growth outlook compared to peers and potential challenges ahead, the analyst has a negative outlook on SI-BONE's stock.
This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.
SI-BONE Inc (SIBN) Analyst Forecast & Price Prediction
Start investing in SI-BONE Inc (SIBN)
Order type
Buy in
Order amount
Est. shares
0 shares